ViatrisHAM:VIA +0.06%60 Market Cap is €16,739 Mil as of Jun. 28, 2026. GuruFocus rates HAM:VIA with a GF Score™ of 60/100 and a GF Value™ of €9.62 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 1,020 Drug Manufacturers companies, Viatris ranks better than 96.86% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Viatris's share price for the quarter that ended in Mar. 2026 was €11.515. Viatris's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 1,164 Mil. Therefore, Viatris's market cap for the quarter that ended in Mar. 2026 was €13,408 Mil.
Viatris's quarterly market cap
increased
from Sep. 2025 (€9,496 Mil) to Dec. 2025 (€12,053 Mil) and
increased
from Dec. 2025 (€12,053 Mil) to Mar. 2026 (€13,408 Mil).
Viatris's annual market cap
increased
from Dec. 2023 (€11,620 Mil) to Dec. 2024 (€14,139 Mil) but then
declined
from Dec. 2024 (€14,139 Mil) to Dec. 2025 (€12,053 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Viatris's Enterprise Value for Today is €27,486 Mil.
Viatris (HAM:VIA) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Viatris Market Cap Related Terms
Viatris Market Cap Historical Data
* Premium members only.
The historical data trend for Viatris's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HAM:VIA vs NBIX, UTHR, ELAN: Market Cap Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Viatris's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Viatris Market Cap vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Viatris's Market Cap distribution charts can be found below:
* The bar in red indicates where Viatris's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Viatris's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Viatris (HAM:VIA) has a Market Cap of €16,739 Mil as of Jun. 28, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Viatris and its competitors. According to the industry distribution chart, Viatris ranks #32 out of 1020 companies in the Drug Manufacturers industry, placing it in the top 3.1%.
Is Viatris' Market Cap too high?
Viatris' current Market Cap is €16,739 Mil. Based on the distribution chart, Viatris ranks #32 out of 1020 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Viatris has a GF Score™ of 60/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Viatris' Market Cap compare to NBIX and UTHR?
According to the Drug Manufacturers industry distribution chart, Viatris ranks #32 out of 1020 companies for Market Cap. This places Viatris in the top 3% of its industry — outperforming the majority of peers. The industry median Market Cap is 204.29. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Drug Manufacturers company?
The median Market Cap among Drug Manufacturers companies is 204.29, based on 1,020 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Viatris and its competitors. For the Drug Manufacturers industry, the median Market Cap is 204.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Viatris's current Market Cap is €16,739 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Viatris stock overvalued right now?
Based on GuruFocus' analysis, Viatris (HAM:VIA) is currently considered Significantly Overvalued. The stock's GF Value™ is €9.62, compared to a current price of €14.26 — trading 48.3% above its estimated fair value. The current Market Cap is €16,739 Mil. Viatris' overall GF Score™ is 60/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Viatris (HAM:VIA), the current Market Cap is €16,739 Mil as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Viatris (HAM:VIA) Overvalued in 2026?
Based on GuruFocus' analysis, Viatris stock appears to be overvalued.
The current stock price of €14.26 is trading 48.3% above its estimated GF Value™ of €9.62.
GuruFocus considers Viatris to be Significantly Overvalued.
Key valuation signals for HAM:VIA:
Market Cap: €16,739 Mil
GF Value™: €9.62 vs. price of €14.26 (48.3% above fair value)
No single metric tells the full story. See the HAM:VIA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.
60GF Score
Get the complete analysis for HAM:VIA
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HAM:VIA has been successfully added to your 
